This dataset is a directory of the different pharmaceutical companies in the United States and the European Union. It includes the company’s specialization, physical address, contact details, email and website links.

Comprehensive dataset containing 10 verified Pharmaceutical company businesses in ME with complete contact information, ratings, reviews, and location data.

This data package consists of bioresearch monitoring information system (BMIS) dataset, directory of the different biotech and biopharmaceutical and pharmaceutical companies in the United States and the European Union, establishment registration database, drug wholesale distributor and third-party logistics provider reporting database, establishment inspections conducted by FDA, and FDA post-marketing requirements and commitments searchable database.

This statistic shows the 2025 ranking of the top 10 biotech and pharmaceutical companies worldwide, based on net income. U.S.-based company Johnson & Johnson was ranked first with a net income of **** billion U.S. dollars. Biotech and pharmaceutical companiesJohnson & Johnson and Merck & Co., both based in the United States, are among the world’s largest biotechnology and pharmaceutical companies based on their net incomes of approximately **** billion U.S. dollars and **** billion U.S. dollars, respectively, as of 2025. Johnson & Johnson generated some **** billion U.S. dollars of revenue in 2024. Pfizer had record-high annual revenues during the COVID-19 vaccination campaign, exceeding 100 billion U.S. dollars in 2022.

Story of a former blockbuster Lyrica was once one of Pfizer’s most successful products. It is an anticonvulsant for neuropathic pain and is also used as therapy for partial seizures. In the EU and in Russia, Lyrica has also been approved to treat general anxiety disorder. In 2017, this prescription medication generated some **** billion U.S. dollars in revenue.

Explore Pharma Data for pharmaceutical companies worldwide with Success.ai. Includes verified SIC codes, firmographic insights, and contact details for decision-makers. Best price guaranteed.

This statistic shows the ranking of the global top 10 biotech and pharmaceutical companies worldwide, based on revenue. The values are based on a 2025 database. U.S. pharmaceutical company Pfizer was ranked first, with a total revenue of around ** billion U.S. dollars. Biotech and pharmaceutical companiesPharmaceutical companies are best known for manufacturing pharmaceutical drugs. These drugs have the aim to diagnose, to cure, to treat, or to prevent diseases. The pharmaceutical sector represents a huge industry, with the global pharmaceutical market being worth around *** trillion U.S. dollars. The best known top global pharmaceutical players are Pfizer, Merck, and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Most of these companies are involved not only in pure pharmaceutical business, but also manufacture medical technology and consumer health products, vaccines, etc. There are both pure play biotechnology companies and pharmaceutical companies which among other products also produce biotech products within their biotechnological divisions. Most of the leading global pharmaceutical companies have biopharmaceutical divisions. Although not a pure play biotech firm, Roche from Switzerland is among the companies with the largest revenues from biotechnology products worldwide. In contrast, California-based company Amgen was one of the world’s first large pure play biotech companies. Biotech companies use biotechnology to generate their products, most often medical drugs or agricultural genetic engineering. The latter segment is dominated by companies like Bayer CropScience and Syngenta. The United Nations Convention on Biological Diversity defines biotechnology as follows: "Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use." In fact, biotechnology is thousands of years old, used in agriculture, food manufacturing and medicine.

Based on revenues latest available as of 2025, Johnson & Johnson was the top ranked pharmaceutical company in the United States. Johnson & Johnson generated around ** billion U.S. dollars worldwide, which is around ** billion U.S. dollars more than the next ranked U.S. pharmaceutical company, Pfizer. However, Johnson & Johnson's total revenue includes also sales from their medical device division, while Pfizer is a pure-play biopharmaceutical company. Branded and generic drugs: What are the differences? Patented products marketed by pharmaceutical companies are referred to as branded. The protection of the patent means that the company, which has spent a large amount of money researching and developing the product, can exclusively sell the drug – often at a high price to recoup its investment. Once the patent expires, other companies may produce generic versions of the product, which contain the same key ingredients.

Comprehensive dataset containing 93 verified Pharmaceutical company businesses in Georgia with complete contact information, ratings, reviews, and location data.

IntroductionInteractions between pharmaceutical companies and healthcare providers are increasingly scrutinized by academics, professionals, media, and politicians. Most empirical studies and professional guidelines focus on unilateral donor-recipient types of interaction and overlook, or fail to distinguish between, more reciprocal types of interaction. However, the degree of goal alignment and potential for value creation differs in these two types of interactions. Failing to differentiate between these two forms of interaction between pharmaceutical companies and healthcare providers could thus lead to biased conclusions regarding their desirability. This study reviews the empirical literature regarding the effects of bilateral forms of interactions between pharmaceutical companies and healthcare providers in order to explore their effects.Material and methodsWe searched two medical databases (i.e. PubMed and Cochrane Library) and one business database (i.e. EBSCO) for empirical, peer-reviewed articles concerning any type of bilateral interaction between pharmaceutical companies and healthcare providers. We included quantitative articles which were written in English and published between January 1st, 2000 and October 31st, 2016, and where the title or abstract included a combination of synonyms of the following keywords: pharmaceutical companies, healthcare providers, interaction, and effects.ResultsOur search results yielded 10 studies which were included in our analysis. These studies focused on either research-oriented interaction or on education-oriented interaction. The included studies reported various outcomes of interaction such as prescribing behavior, ethical dilemmas, and research output. Regardless of the type of interaction, the studies either reported no significant effects or ambivalent outcomes such as affected clinical practice or ethical issues.Discussion and conclusionThe effects of bilateral interactions reported in the literature are similar to those reported in studies concerning unilateral interactions. The theoretical notion that bilateral interactions between pharmaceutical companies and healthcare providers have different effects given their increased level of goal alignment thus does not seem to hold. However, most of the empirical studies focus on intermediary, provider-level, outcomes such as altered prescribing behavior. Outcomes at the health system level such as overall costs and quality of care are overlooked. Further research is necessary in order to disentangle various forms of value created by different types of interactions between pharmaceutical companies and healthcare providers.

Comprehensive dataset containing 138 verified Pharmaceutical company businesses in Finland with complete contact information, ratings, reviews, and location data.

About the Dataset: Pharmaceutical Products Pricing and Availability Data in Pakistan

This dataset contains information about pharmaceutical product pricing and availability in Pakistan. The data was collected from various sources and compiled into a structured format for analysis. The dataset consists of 1630 entries with 7 columns, including:

Name: The name of the pharmaceutical product. Company: The company manufacturing or distributing the product. Price_before: The product's price before any discount is applied. Discount: The discount offered on the product, if applicable. Price_After: The price of the product after applying any discount. Pack_Size: The size or quantity of the product's packaging. Availability: The availability status of the product.

The dataset provides insights into the pricing trends and availability of pharmaceutical products in Pakistan, which can be valuable for various stakeholders including consumers, healthcare professionals, and policymakers. It can be used for analysis, research, and decision-making in the pharmaceutical industry.

Data Overview: Entries: 1630 Missing Values: Some columns have missing values, such as 'Name', 'Company', 'Price_before', 'Discount', 'Price_After', 'Pack_Size', and 'Availability'. Data Types: The dataset consists of object types for textual data and one float type for numerical data.

Potential Uses: This dataset can be used for a variety of purposes, including:

• Analyzing pricing trends and patterns of different drugs in Pakistan.
• Studying the affordability and accessibility of essential medicines in Pakistan.
• Tracking the performance of different pharmaceutical companies in the Pakistani market.
• Identifying potential areas for improving access to affordable medicines in Pakistan.

Limitations: It is important to note that this dataset only includes data on the maximum retail prices of pharmaceutical products. The actual price consumers pay may vary depending on the pharmacy and other factors. Additionally, the dataset does not include information on the quality of the pharmaceutical products.

I hope this description is helpful!

In 2022, U.S.-based company Tempus was the world's leading data processor for drug development based on investments. Investments for the company stood at *** billion U.S. dollars that year. Tempus uses advanced data analytics and artificial intelligence/machine learning for drug discovery and development.

Comprehensive dataset containing 98 verified Pharmaceutical company businesses in Norway with complete contact information, ratings, reviews, and location data.

Comprehensive dataset containing 47 verified Pharmaceutical company businesses in XK with complete contact information, ratings, reviews, and location data.

🧪 Discover the Power of a Verified Pharma Database in IndiaIn a fast-evolving healthcare ecosystem, pharmaceutical businesses, distributors, medical marketers, and health-tech startups need access to real-time, accurate, and structured pharma data to make informed decisions and scale their operations.…

Popular Pharmaceutical Companies Export Import Data. Follow the Eximpedia platform for HS code, importer-exporter records, and customs shipment details.

The data include information on (1) Pharmaceutical companies; (2) Pharma Group each of these companies belong to; (3) Patent application to the European Patent Office by pharmaceutical company (assignee); (4) Name of inventors (i.e. employees of a pharmaceutical company) that appear on the patent. The data include unique identifiers that can be used to link a pharma company to a pharma group and to link a pharma company to the patent assignee (i.e. the legal entity that applies for the patent). These data are particularly useful to track the employment history of inventors following a M&A. For instance, Schering-Plough was acquired by Merck and Co in 2009. So if a scientist working for Shering-Plough before 2009 appears after the acquisition on a patent owned by Merck, we can infer that this employee has not changed company (i.e. she keeps working for the company that bought the company she was working for).

Productivity is a main driver of economic growth and a key indicator of a country's competitiveness. At the launch of the ESRC Productivity Insights Network, Lord Jim O'Neill, chair of the International Advisory Board, said that "raising productivity is arguably the central economic challenge in the UK, but to achieve this we need to better understand the drivers and inhibitors of productivity". Although not all the factors that influence productivity are well understood, there is consensus among economists that innovation is one of its main determinants. Understanding how changes in market structure and in firms' organization affect innovation is then vital to unlock an important piece of the productivity conundrum.

One question that has recently gained central stage in the economic debate on innovation is how Mergers and Acquisitions (M&As) affect firms' research efforts and output. The view taken by the European Commission in recent merger cases is that M&As involving highly innovative companies in concentrated industries are likely to decrease R&D effort and innovation. However, recent theoretical studies show that M&As may spur or stifle innovation depending on the assumption made about the R&D technology, the synergies arising from the merger and changes in the appropriability of the innovation. The question whether M&As have a positive or a negative impact on innovation is therefore, ultimately, an empirical one. Unfortunately, the available evidence does not seem to be conclusive either. The aim of this project is then to provide fresh evidence on this relevant policy issue. While most of the existing literature has looked at the effect of M&As on innovation using firm-level data, the main novelty of this project is that we will investigate how M&As influence the productivity of individual inventors, using patent data in the Pharmaceutical Industry.

The use of data at inventor level presents at least two important advantages compared to firm-level analysis. First, inventor-level data will allow us to identify the causal effect of M&As on innovation in a more rigorous way. In this study, we will compare the productivity of inventors that work for companies that merge to that of an unusually large pool of inventors that work for firms not involved in a merger and have very similar research output up to the year of the merger. Moreover, changes in productivity at inventor level are easier to measure because individuals, differently from firms, do not physically merge into a new entity. Second, inventor-level data will allow us to explore the mechanisms through which M&As affect inventors' productivity and whether they can truly favour knowledge synergies between teams of scientists, as their proponents often claim. One specific objective of this project is to investigate whether inventors' productivity varies systematically with changes in their research team or with the degree of overlapping in their research programs.

The choice of the pharma industry to investigate these questions presents also several advantages. First, this is a highly innovative industry, employing more than 70,000 people in UK only. Second, most of the largest pharma companies currently active on the market have been involved in one or more M&As over the last three decades. Third, patents provide an accurate measure of the research output of pharma companies because they are the only effective way to protect innovation in this industry, whereas other sectors can rely on other strategies, such as trade secrecy.

By studying how M&As affect scientists' job departure and network of collaborators and, in turn, their innovative output, this research will provide vital evidence to inform on-going debates in competition policy as well as to improve our understanding of Business Environment and People two of the five pillars identified by the UK government as necessary to increasing productivity.

Objective: To examine company characteristics associated with better transparency and to apply a tool used to measure and improve clinical trial transparency among large companies and drugs, to smaller companies and biologics.

Design: Cross-sectional descriptive analysis.

Setting and participants. Novel drugs and biologics FDA approved in 2016 and 2017, and their company sponsors.

Using established Good Pharma Scorecard (GPS) measures, companies and products were evaluated on their clinical trial registration, results dissemination, and FDA Amendments Act (FDAAA) implementation; Companies were ranked using these measures and a multi-component data sharing measure. Associations between company transparency scores with company size (large vs non-large), location (US vs non-US), and sponsored product type (drug vs biologic) were also examined. 26% of products (16/62) had publicly available results for all clinical trials supporting their FDA approval and 67% (39/58) had public res...

Comprehensive dataset containing 2,093 verified Pharmaceutical company businesses in Italy with complete contact information, ratings, reviews, and location data.